Ipamorelin is a selective growth hormone secretagogue that stimulates GH pulses without increasing cortisol or prolactin, commonly utilized for muscle growth, fat loss, and improved sleep quality. Users typically run a daily dose of 200 mcg, often following a five-days-on, two-days-off cycle. While users frequently report changes in sleep patterns and vivid dreams, and occasionally note fluid retention, injection-site reactions and GI distress have not been consistent themes. The primary tradeoff is that all human use remains off-label, and the clinical evidence base for its exploratory indications is significantly thinner than the current community discourse suggests.
Data last updated
Measured on 5 of 6 axes
Evidence shape
Ipamorelin currently holds a low tier of evidence, supported by only three published human studies focused on diagnostic, mechanistic, and treatment-based applications. While the literature includes two completed registered trials, the breadth of research remains thin, with most indications relying on single-trial data or preclinical models. The absence of large-scale, multi-trial validation for any specific clinical outcome signals that the current evidence base is exploratory and lacks the robust, replicated results required to establish standard therapeutic efficacy.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Gastrointestinal Dysmotility
1 study · 1 completed
Ileus
1 study · 1 completed
Treatment studies
1 study
Diagnostic & mechanistic studies
2 studies
2 completed study rows are present, but endpoint pass/fail classification is still pending.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How Ipamorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
In research trials, Ipamorelin was administered intravenously at a dose of 0.03–0.06 mg per kilogram of body weight, given two to three times each day.
No structured protocol details captured for this tier yet.
Most of the 133 community reports didn't specify a dosing schedule; among those who did, daily dosing was most common at around 300 mcg subQ, with a smaller group dosing twice daily at roughly 250 mcg. About six reported a 5-days-on, 2-days-off cycle.